Expression of epithelial-mesenchymal transition markers E-cadherin and ZEB1 in colorectal cancer

Purpose of the study. Evaluation of expression of the epithelial-mesenchymal transition markers E-cadherin and ZEB1 in patients with stage II-IV colorectal cancer (CRC).Materials and methods. The study included operational material obtained from 299 patients aged 42–86 years (mean age 64.2±1.7 years...

Full description

Saved in:
Bibliographic Details
Main Authors: I. A. Novikova, O. I. Kit
Format: Article
Language:Russian
Published: QUASAR, LLC 2021-06-01
Series:Исследования и практика в медицине
Subjects:
Online Access:https://www.rpmj.ru/rpmj/article/view/719
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849688398892105728
author I. A. Novikova
O. I. Kit
author_facet I. A. Novikova
O. I. Kit
author_sort I. A. Novikova
collection DOAJ
description Purpose of the study. Evaluation of expression of the epithelial-mesenchymal transition markers E-cadherin and ZEB1 in patients with stage II-IV colorectal cancer (CRC).Materials and methods. The study included operational material obtained from 299 patients aged 42–86 years (mean age 64.2±1.7 years) with stage II-IV CRC treated at National Medical Research Centre for Oncology in 2013-2017. Stage II CRC (T3-4 N0 M0 ) was diagnosed in 110 patients, stage III (T1-4 N1-2 M0 ) – in 88 patients, stage IV (T1-4 N0-2 M1 ) – in 101 patients. Polyclonal rabbit antibodies to ZEB1 (Biorbyt Ltd., UK) and mouse monoclonal antibodies to E-cadherin (Diagnostic BioSystems, USA) were used for an IHC analysis. The intensity and degree of tumor cell staining, percentage of stained tumor cells in the sample and the number of patients with positive and negative marker expression were determined. Groups were compared using the Mann–Whitney U test and the Pearson's chi-square test.Results. Positive expression of E-cadherin was found in 64.5 % (193 of 299 patients), ZEB1 – in 80.6 % (241 of 299 patients). The number of patients with E-cadherin-positive tumors statistically significantly decreased (χ2 =15.888 at p<0.001) from stage II to stage IV, while for ZEB1, on the contrary, it statistically significantly increased (χ2 =43.912 at p><0.001) from stage II to stage IV. The mean values of expression in positively stained cells were: in stage II – E-cadherin 55.3±6.8 %, ZEB1 43.0±5.9 %; in stage III – E-cadherin 38.4±5.8 %, ZEB1 77.0±5.5 %; in stage IV – E-cadherin 14.7±4.7 %, ZEB1 76.9±3.5 %. Significant differences were observed between the mean values of ZEB1 expression in stages III and IV compared to stage II, as well as between the mean values of E-cadherin expression in stages II and III compared to stage IV (p><0.05). No significant differences were found in the mean values of ZEB1 and E-cadherin expression in stages III and IV, II and III respectively.Conclusions. The study demonstrated statistically significant relationship between tumor stages and expression of E-cadherin and ZEB1 in the epithelial-mesenchymal transition. The loss of the E-cadherin expression in tumor cells of patients from stage II to stage IV and increased expression of ZEB1 in the studied groups were statistically significant (p<0.05).
format Article
id doaj-art-d85efd46ef814e20901660500c18d9e3
institution DOAJ
issn 2410-1893
language Russian
publishDate 2021-06-01
publisher QUASAR, LLC
record_format Article
series Исследования и практика в медицине
spelling doaj-art-d85efd46ef814e20901660500c18d9e32025-08-20T03:22:00ZrusQUASAR, LLCИсследования и практика в медицине2410-18932021-06-0182233310.17709/2410-1893-2021-8-2-2374Expression of epithelial-mesenchymal transition markers E-cadherin and ZEB1 in colorectal cancerI. A. Novikova0O. I. Kit1National Medical Research Centre for Oncology of the Ministry of Health of RussiaNational Medical Research Centre for Oncology of the Ministry of Health of RussiaPurpose of the study. Evaluation of expression of the epithelial-mesenchymal transition markers E-cadherin and ZEB1 in patients with stage II-IV colorectal cancer (CRC).Materials and methods. The study included operational material obtained from 299 patients aged 42–86 years (mean age 64.2±1.7 years) with stage II-IV CRC treated at National Medical Research Centre for Oncology in 2013-2017. Stage II CRC (T3-4 N0 M0 ) was diagnosed in 110 patients, stage III (T1-4 N1-2 M0 ) – in 88 patients, stage IV (T1-4 N0-2 M1 ) – in 101 patients. Polyclonal rabbit antibodies to ZEB1 (Biorbyt Ltd., UK) and mouse monoclonal antibodies to E-cadherin (Diagnostic BioSystems, USA) were used for an IHC analysis. The intensity and degree of tumor cell staining, percentage of stained tumor cells in the sample and the number of patients with positive and negative marker expression were determined. Groups were compared using the Mann–Whitney U test and the Pearson's chi-square test.Results. Positive expression of E-cadherin was found in 64.5 % (193 of 299 patients), ZEB1 – in 80.6 % (241 of 299 patients). The number of patients with E-cadherin-positive tumors statistically significantly decreased (χ2 =15.888 at p<0.001) from stage II to stage IV, while for ZEB1, on the contrary, it statistically significantly increased (χ2 =43.912 at p><0.001) from stage II to stage IV. The mean values of expression in positively stained cells were: in stage II – E-cadherin 55.3±6.8 %, ZEB1 43.0±5.9 %; in stage III – E-cadherin 38.4±5.8 %, ZEB1 77.0±5.5 %; in stage IV – E-cadherin 14.7±4.7 %, ZEB1 76.9±3.5 %. Significant differences were observed between the mean values of ZEB1 expression in stages III and IV compared to stage II, as well as between the mean values of E-cadherin expression in stages II and III compared to stage IV (p><0.05). No significant differences were found in the mean values of ZEB1 and E-cadherin expression in stages III and IV, II and III respectively.Conclusions. The study demonstrated statistically significant relationship between tumor stages and expression of E-cadherin and ZEB1 in the epithelial-mesenchymal transition. The loss of the E-cadherin expression in tumor cells of patients from stage II to stage IV and increased expression of ZEB1 in the studied groups were statistically significant (p<0.05).https://www.rpmj.ru/rpmj/article/view/719colorectal cancerepithelial-mesenchymal transitionimmunohistochemical studybiomarkersexpression levele-cadherinzeb1
spellingShingle I. A. Novikova
O. I. Kit
Expression of epithelial-mesenchymal transition markers E-cadherin and ZEB1 in colorectal cancer
Исследования и практика в медицине
colorectal cancer
epithelial-mesenchymal transition
immunohistochemical study
biomarkers
expression level
e-cadherin
zeb1
title Expression of epithelial-mesenchymal transition markers E-cadherin and ZEB1 in colorectal cancer
title_full Expression of epithelial-mesenchymal transition markers E-cadherin and ZEB1 in colorectal cancer
title_fullStr Expression of epithelial-mesenchymal transition markers E-cadherin and ZEB1 in colorectal cancer
title_full_unstemmed Expression of epithelial-mesenchymal transition markers E-cadherin and ZEB1 in colorectal cancer
title_short Expression of epithelial-mesenchymal transition markers E-cadherin and ZEB1 in colorectal cancer
title_sort expression of epithelial mesenchymal transition markers e cadherin and zeb1 in colorectal cancer
topic colorectal cancer
epithelial-mesenchymal transition
immunohistochemical study
biomarkers
expression level
e-cadherin
zeb1
url https://www.rpmj.ru/rpmj/article/view/719
work_keys_str_mv AT ianovikova expressionofepithelialmesenchymaltransitionmarkersecadherinandzeb1incolorectalcancer
AT oikit expressionofepithelialmesenchymaltransitionmarkersecadherinandzeb1incolorectalcancer